Qing Liu, M.S.

Pfizer Inc.

Disclosure(s): Pfizer Inc.: Stocks/Bonds (Public Company)

Poster(s):

• (P-40) Impact of case and control selection on influenza vaccine effectiveness (VE) among adults aged 40 years and older hospitalized with acute respiratory illness (ARI) during 2022-2023 using a test negative design (TND): secondary analysis of the North America multi-specimen study
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT

• (P-604) Preliminary real-world Abrysvo vaccine effectiveness (VE) against Respiratory Syncytial Virus (RSV)-related lower respiratory tract disease (LRTD) hospitalizations and emergency department (ED) visits—Kaiser Permanente of Southern California (KPSC), November 2023-April 2024
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT

• (P-681) Estimated Incidence of Respiratory Syncytial Virus (RSV)-related Hospitalizations for Acute Respiratory Infections (ARIs), including Community Acquired Pneumonia (CAP), in Adults in Germany
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT